External Beam Radiotherapy for Prostate Cancer: Urinary Outcomes for Men With High International Prostate Symptom Scores (IPSS)

(A) Trend in International Prostate Symptom Score (IPSS) for the entire cohort of men with pre–radiotherapy (RT) IPSS ≥15 at first follow-up (F/U) (median, 5 weeks) and last follow-up (median, 40 months). Blue, black, and red lines represent 75% quartile scores, median scores, and 25% quartile scores, respectively. Dotted lines represent range of IPSS. (B) Patient declines in IPSS at first follow-up (median, 5 weeks) and last follow-up (median, 40 months) compared with pre-RT IPSS. Blue, black, and red lines represent 75% quartile scores, median scores, and 25% quartile scores, respectively. Dotted lines represent range of values. Mean change from baseline to first follow-up, −3.6 points (95% confidence interval, −5.5 to −1.7; p < 0.0004); mean change from baseline to last follow-up, −6.9 points (95% confidence interval, −8.9 to −4.9; p < 0.0001).

American Urological Association (AUA) symptom classification impacts the change in International Prostate Symptom Score (IPSS) from baseline to last follow-up. RT = radiotherapy. Blue, black, and red lines represent 75% quartile scores, median scores, and 25% quartile scores, respectively. Dotted lines represent range of values.

(A) Men with a baseline International Prostate Symptom Score (IPSS) ≥15 have a statistically significant difference in freedom from Grade ≥2 Late Radiation Therapy Oncology Group (RTOG) genitourinary (GU) toxicity after external beam radiotherapy (EBRT) vs. men with a baseline IPSS ≤14. (B) Men with a baseline IPSS ≥15 have no statistically significant difference in freedom from Grade ≥3 Late RTOG GU toxicity after EBRT vs. men with a baseline IPSS ≤14.